🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

AMN Healthcare Services, Inc. AMN R2KR3KPHARMA

Healthcare · Medical Care Facilities · United States
https://www.amnhealthcare.com
Company Profile ↓
$48.01
+157.56% 1Y
Mkt Cap$1.86B
P/E17.91
P/B1.91
52W High$48.01
52W Low$15.10
Book Value$19.15
EPS (TTM)$2.68

Company Overview

AMN Healthcare Services, Inc. provides technology-enabled healthcare workforce solutions and staffing services to acute and sub-acute care hospitals, and other healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. It offers travel nurse staffing, labor disruption staffing, local staffing, international nurse permanent placement, allied staffing, crisis nurse staffing for critical staffing and rapid response nursing, and allied health professionals, such as skilled nursing facilities, rehabilitation clinics, schools, and pharmacies, as well as physician and advanced practice staffing, and revenue cycle solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists; and solutions for schools, including teletherapy platform, Televate, and qualified school speech-language pathologists, psychologists, nurses, social workers, and other care providers. In addition, it offers locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. Additionally, the company provides language services, vendor management systems, workforce optimization, and outsourced solutions. The company offers its services under the brands, including AMN Healthcare, Nursefinders, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is based in Dallas, Texas.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 15.6%, reflecting efficient use of shareholder capital.

Reasonable Valuation

Trades at a P/E of 17.9, below the sector median of 25.4.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $2.73B (-8.5% YoY); net profit $-95.70M.
  • Trailing 12 Months Year-on-year growth — revenue +2.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 8.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:8.32%
1 Year:2.30%

Stock Price Performance

1 Year:+157.56%
6 Months:+135.92%
3 Months:+43.53%
1 Month:+38.92%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
$15.10 $48.01
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)88.28 · Overbought
Price Performance
1M+38.92%
3M+43.53%
6M+135.92%
1Y+157.56%
Valuation vs Sector

P/E of 17.91 is below the sector median of 25.45 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • RSI at 88 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
17.91
Industry PE
25.45
Forward P/E
51.14
PEG Ratio
1.22
Book Value
$19.15
Price to Book
1.91
P/S
0.41
EV/EBITDA
5.95
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
8.32%
Profit 5Y
-
Revenue (YoY)
2.30%
Earnings (YoY)
-

Profitability & Returns

ROCE
2.19%
ROE
15.56%
ROA
4.39%
Profit Margin
3.06%
Op Margin
4.00%
Gross Margin
27.79%
EPS (Latest Qtr)
$0.53
EPS (TTM)
$2.68

Balance Sheet & Liquidity

Debt/Equity
1.05
Quick Ratio
1.03
Current Ratio
1.13
Debt
$775.81M
Total Assets
$2.36B
Current Assets
$1.14B
Working Capital
$-32.24M

Ownership

Promoter Holding
0.97%
Chg in Prom Hold
0.00%
FII / Inst Holding
125.01%
Chg in FII Hold
0.18%

Financial Snapshot

Enterprise Value
$1.86B
Total Revenue (TTM)
$3.43B
EBITDA
$307.29M
Free Cash Flow
$445.77M
Operating Cash Flow
$470.76M
Shares Outstanding
38.73M
Gross Margin
27.79%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AMN AMN Healthcare Services, Inc. R2KR3KPHARMA 48.01 17.91 $1.86B 0.00% 2.19% 15.56% 8.32% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ------495.17M489.80M494.41M509.08M522.49M558.11M526.84M528.63M532.44M535.18M567.60M586.89M602.46M608.35M551.63M631.27M885.95M857.45M877.80M1.55B1.43B1.14B1.13B991.30M853.46M820.88M740.68M-689.53M658.17M634.50M748.23M1.38B673.24M
Cost of Revenue ----------------------------------491.41M461.78M450.08M553.10M1.01B-
Gross Profit 126.01M131.80M151.90M154.75M154.47M158.61M161.78M161.01M159.54M162.09M167.82M180.96M175.15M172.46M176.76M179.54M190.03M197.13M202.07M197.54M184.63M207.54M288.87M280.54M305.87M496.17M460.24M385.03M368.85M330.28M289.51M257.51M229.83M-198.12M196.40M184.41M195.13M368.84M205.88M
Operating Expenses ----------------------------------185.61M192.34M175.97M186.97M251.66M-
Operating Income 37.61M-47.31M47.88M46.68M-52.03M56.38M50.83M-55.20M54.81M42.63M-45.05M45.16M39.74M-35.74M38.40M46.46M-104.40M99.17M105.83M207.93M183.53M136.37M125.67M91.66M86.93M39.95M37.68M-12.51M4.06M8.44M8.16M117.17M26.91M
EBITDA ----------------------------------52.36M-83.83M87.25M45.35M152.83M-
Interest Expense ----------------------------------12.32M11.36M9.63M12.28M6.71M-
Pretax Income ----------------------------------183.00K-135.07M37.99M-4.16M110.46M-
Tax Provision ----------------------------------1.27M-18.87M8.70M3.53M48.29M-
Net Income 33.65M20.16M25.87M26.32M27.30M26.35M32.01M31.25M28.13M41.17M42.68M35.53M27.92M35.61M34.12M28.87M23.52M27.48M12.96M22.32M26.07M9.31M70.38M66.77M74.02M146.01M123.80M92.44M84.11M60.91M53.17M17.33M16.24M--1.09M-116.20M29.29M-7.70M62.17M21.16M
Diluted EPS 0.690.410.530.530.550.540.650.630.570.840.870.730.580.740.710.610.490.580.270.470.550.191.471.391.543.092.772.102.021.551.390.450.42--0.03-3.020.76-0.201.590.53

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 759.79M669.91M887.47M953.95M1.01B1.04B1.46B1.90B1.99B2.14B2.22B2.39B3.98B5.24B3.79B2.98B2.73B
Cost of Revenue -------------3.53B2.54B2.06B1.96B
Gross Profit 204.42M184.36M249.32M270.40M297.28M316.12M469.36M619.72M644.42M696.38M743.47M791.78M1.31B1.72B1.25B919.38M774.06M
Operating Expenses -------------1.07B903.35M799.59M740.89M
Operating Income -153.61M-43.78M37.65M53.34M65.50M67.90M128.88M191.63M212.44M202.83M176.91M149.26M478.00M647.10M346.23M119.78M33.17M
EBITDA -------------784.21M499.36M71.11M101.13M
Interest Expense -------------40.40M54.14M69.90M45.59M
Pretax Income -------------606.70M284.29M-172.57M-101.06M
Tax Provision -------------162.65M73.61M-25.59M-5.36M
Net Income -122.18M-51.99M-26.27M17.14M32.93M33.22M81.89M105.84M132.56M141.74M113.99M70.67M327.39M444.05M210.68M-146.98M-95.70M
Diluted EPS -3.75-1.49-0.570.370.690.691.682.152.682.912.401.486.819.905.36-3.85-2.48

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --562.11M535.63M517.39M604.29M680.73M880.43M1.19B1.25B1.49B1.93B2.35B-2.89B2.92B2.42B2.09B
Current Assets --------------1.09B841.68M594.91M545.38M
Cash & Equivalents 11.32M27.05M1.88M3.96M5.68M15.58M13.07M9.58M10.62M15.15M13.86M82.98M29.21M-64.52M32.94M10.65M33.97M
Inventory ------------------
Receivables --------------944.38M741.19M508.30M430.60M
Total Liabilities --380.28M375.90M335.27M386.55M424.15M532.57M737.50M691.43M853.73M1.19B1.53B-1.84B2.09B1.71B1.45B
Current Liabilities --117.89M140.05M109.53M143.09M178.29M251.02M274.79M265.27M307.27M378.11M422.96M-857.93M656.12M545.78M577.61M
Long Term Debt ---174.20M158.18M148.67M144.38M180.99M359.19M319.84M440.61M617.16M857.96M-843.50M1.30B1.06B767.05M
Total Debt --------------860.96M1.35B1.10B803.20M
Total Equity 284.13M170.84M153.46M135.66M182.11M217.74M256.58M347.86M449.38M562.53M638.99M736.74M819.68M-1.04B831.26M706.62M642.11M
Shares Outstanding --------------50.11M50.42M50.69M51.05M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 98.73M8.09M19.31M58.38M60.17M27.68M56.31M133.91M160.52M226.99M224.86M256.83M-653.73M372.17M320.42M269.46M
Investing Cash Flow -29.25M-6.85M-1.98M1.58M-49.20M-28.23M-116.08M-258.36M-35.36M-279.34M-291.82M-538.17M--170.71M-412.49M-79.94M4.30M
Financing Cash Flow -53.81M-26.45M-15.30M-58.17M-1.02M-2.10M56.20M126.29M-77.19M37.51M136.60M211.49M--591.87M10.73M-259.45M-295.89M
Capital Expenditure -3.79M-4.17M-4.65M-5.47M-9.05M-19.13M-27.01M-21.96M-26.53M-35.21M-35.22M-37.70M--80.92M-105.39M-80.89M-35.63M
Free Cash Flow 94.94M3.92M14.66M52.91M51.12M8.54M29.30M111.95M133.99M191.79M189.64M219.12M-572.81M266.78M239.53M233.83M
Net Change in Cash --------------108.84M-29.60M-18.97M-22.13M
Share Buybacks -----0013.26M20.16M67.01M18.70M02.69M576.77M424.74M00

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 26.9%27.5%28.1%28.3%29.4%30.5%32.1%32.6%32.4%32.6%33.5%33.1%32.9%32.7%33.0%30.8%28.3%
Operating Margin % -20.2%-6.5%4.2%5.6%6.5%6.6%8.8%10.1%10.7%9.5%8.0%6.2%12.0%12.3%9.1%4.0%1.2%
Net Margin % -16.1%-7.8%-3.0%1.8%3.3%3.2%5.6%5.6%6.7%6.6%5.1%3.0%8.2%8.5%5.6%-4.9%-3.5%
ROE % -71.5%-33.9%-19.4%9.4%15.1%12.9%23.5%23.6%23.6%22.2%15.5%8.6%-42.5%25.3%-20.8%-14.9%
ROCE % --9.9%9.5%13.1%14.2%13.5%20.5%21.0%21.5%17.1%11.4%7.7%-31.9%15.3%6.4%2.2%

Shareholding Pattern

Insiders
0.97%
Institutions
125.01%
Public Float
126.24%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 17.15% 6.64M $242.62M
2 Morgan Stanley 5.89% 2.28M $83.36M
3 Vanguard Capital Management LLC 4.44% 1.72M $62.78M
4 State Street Corporation 4.37% 1.69M $61.88M
5 Boston Partners 4.32% 1.67M $61.15M
6 Allianz Asset Management GmbH 3.62% 1.40M $51.24M
7 Arrowstreet Capital, Limited Partnership 3.59% 1.39M $50.83M
8 Vanguard Portfolio Management LLC 3.33% 1.29M $47.04M
9 Dimensional Fund Advisors LP 3.31% 1.28M $46.87M
10 Two Sigma Investments, LP 2.99% 1.16M $42.30M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AMN

Yahoo Finance Fri, 23 Oct 2026

Strength Seen in AMN Healthcare (AMN): Can Its 8.9% Jump Turn into More Strength?

AMN Healthcare (AMN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.…

Yahoo Finance Sat, 17 Oct 2026

Did Falling Travel Assignments Just Shift AMN Healthcare Services (AMN) Stock Narrative?

AMN Healthcare Services has seen travelers on assignment fall over the past two years, alongside a 7.6% annual decline in earnings per share and weakening returns on capital, highlighting ongoing operational and financial pressure. The comb…

Yahoo Finance Mon, 12 Oct 2026

Here's Why You Should Retain AMN Stock in Your Portfolio for Now

AMN Healthcare's staffing demand, technology investments and growth prospects fuel optimism, but pricing pressure and segment weakness pose challenges.

Yahoo Finance Fri, 09 Oct 2026

AMN Healthcare Services (AMN) Stock Could Be Reasonable On Its 134% YTD Run

AMN Healthcare Services has seen its share price move sharply this year, which puts fresh attention on whether the current valuation lines up with the cash the business can realistically generate over time. With that kind of shift on the sc…

Yahoo Finance Wed, 07 Oct 2026

Dassault Aviation: Total number of shares and voting rights - 30 09 26

DASSAULT AVIATION French corporation (société anonyme) with a share capital of 61,754,887.20 euros Headquarters: 78, quai Marcel Dassault 92210 SAINT-CLOUD 712 042 456 RCS Nanterre Information concerning the total number of voting rights an…

Yahoo Finance Wed, 07 Oct 2026

2 Profitable Stocks with Exciting Potential and 1 We Ignore

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.…

AMN — Frequently Asked Questions

What is the current share price of AMN Healthcare Services, Inc. (AMN)?

As of 2026-10-23 16:27 PDT, AMN Healthcare Services, Inc. (AMN) trades at $48.01 on NYSE. Its 52-week range is $15.10 to $48.01.

What is the market capitalisation of AMN?

AMN Healthcare Services, Inc. (AMN) has a market capitalisation of $1.86B on NYSE.

What is the P/E ratio of AMN?

AMN trades at a trailing price-to-earnings (P/E) ratio of 17.91. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.91.

What is the return on equity (ROE) of AMN?

AMN has a return on equity (ROE) of 15.56%. Its return on capital employed (ROCE) is 2.19%.

Is AMN a good stock to buy?

This page provides a data-driven analysis of AMN Healthcare Services, Inc. (AMN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space